Skip to main content

Kenvue Inc. (KVUE) Stock Analysis

Recovery setup

HoldModerate Confidence

Consumer Defensive · Household & Personal Products

Hold if already holding. Not a fresh buy at $17.23, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.67).

Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care (Tylenol, Zyrtec, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (Listerine, BAND-AID, Johnson's). Products are sold in 165+... Read more

$17.23+0.5% A.UpsideScore 5.5/10#3 of 13 Household & Personal Products
QualityF-score7 / 9FCF yield5.66%
IncomeYield4.85%Payout98.51%at-risk
Stop $16.50Target $17.33(resistance)A.R:R -0.3:1
Analyst target$19.50+13.2%12 analysts
$17.33our TP
$17.23price
$19.50mean
$23

Hold if already holding. Not a fresh buy at $17.23, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.67). Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.

Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.

Val6.2Qual6.3Grw6.8Mom3.1Sent5.3Ins5.0Peer4.6Tech4.8Risk6.15.5OVERALL

Recent Developments — Kenvue Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Sector modifier (Consumer Defensive): +0.8
Strong earnings beat streak (3/4)
Risks
Analyst target reached - limited upside remaining
Negative news sentiment (-0.67)
Negative momentum

Key Metrics

P/E (TTM)20.4
P/E (Fwd)13.8
Mkt Cap$32.9B
EV/EBITDA11.7
Profit Mgn10.6%
ROE15.7%
Rev Growth4.5%
Beta0.52
Dividend4.85%
Rating analysts20

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C1.47bearish
IV62%elevated
Max Pain$5-71.0% vs spot

Material Events(8-K, last 90d)

  • 2026-02-12Item 5.02HIGH
    CFO Amit Banati notified company he will step down effective May 12, 2026 to become CEO of another company. No successor named at time of filing; company intends to appoint an interim principal financial officer pending merger with Kimberly-Clark.
    SEC filing →
  • 2026-02-17Item 2.05MEDIUM
    Board approved a restructuring initiative on February 17, 2026. Financial details and scope of exit/disposal activities disclosed. No specific charges quantified in available body text.
    SEC filing →
  • 2026-04-15Item 5.02MEDIUM
    Heather Howlett (current CAO) appointed as interim CFO and CAO effective May 12, 2026, succeeding departing CFO Amit Banati. Monthly stipend of $125,000 added to current compensation. Interim designation in light of pending Kimberly-Clark merger.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
4.5
Macd
6.0
Volume distribution (falling OBV)Below 200-MA, MA slope -2.9%/30d — confirmed downtrend
GatesMomentum 3.1<4.5A.R:R -0.3=NEGATIVEDeath cross (50MA < 200MA)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 80d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
48 · Neutral
↑ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $16.81Resistance $17.68

Price Targets

$17
$17
A.Upside+0.6%
A.R:R-0.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (-1.6% upside)
! Momentum score 3.1/10 — below 4.5 minimum
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-06 (80d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is KVUE stock a buy right now?

Hold if already holding. Not a fresh buy at $17.23, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.67). Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Target $17.33 (+0.6%), stop $16.50 (−4.4%), A.R:R -0.3:1. Score 5.5/10, moderate confidence.

What is the KVUE stock price target?

Take-profit target: $17.33 (+0.5% upside). Target $17.33 (+0.6%), stop $16.50 (−4.4%), A.R:R -0.3:1. Stop-loss: $16.50.

What are the risks of investing in KVUE?

Analyst target reached - limited upside remaining; Negative news sentiment (-0.67); Negative momentum.

Is KVUE overvalued or undervalued?

Kenvue Inc. trades at a P/E of 20.4 (forward 13.8). TrendMatrix value score: 6.2/10. Verdict: Hold.

What do analysts say about KVUE?

20 analysts cover KVUE with a consensus score of 2.8/5. Average price target: $20.

What does Kenvue Inc. do?Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care...

Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care (Tylenol, Zyrtec, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (Listerine, BAND-AID, Johnson's). Products are sold in 165+ countries; the company has a pending merger with Kimberly-Clark announced November 2025.

Related stocks: ELF (e.l.f. Beauty, Inc.) · UL (Unilever PLC) · CL (Colgate-Palmolive Company) · KMB (Kimberly-Clark Corporation) · CHD (Church & Dwight Company, Inc.)